Suven Life Sciences has allotted 44,77,612 equity shares on preferential basis up on conversion of equivalent number of convertible warrants. Consequently, the paid up equity share capital has increased to 23,19,51,819 equity shares of Re 1 each. Powered by Capital Market - Live News

Net Loss of Suven Life Sciences reported to Rs 101.92 crore in the quarter ended December 2025 as against net loss of Rs 39.12 crore during the previous quarter ended December 2024. Sales rose 74.53% to Rs 2.81 crore in the quarter ended December 2025 as against Rs 1.61 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2.811.61 75 OPM %-3677.94-2435.40 - PBDT-100.58-37.58 -168 PBT-101.92-39.12 -161 NP-101.92-39.12 -161 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live News

Net Loss of Suven Life Sciences reported to Rs 77.31 crore in the quarter ended September 2025 as against net loss of Rs 49.64 crore during the previous quarter ended September 2024. Sales declined 64.20% to Rs 0.92 crore in the quarter ended September 2025 as against Rs 2.57 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales0.922.57 -64 OPM %-8670.65-2031.52 - PBDT-75.99-48.19 -58 PBT-77.31-49.64 -56 NP-77.31-49.64 -56 Powered by Capital Market - Live News

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 11 November 2025.Powered by Capital Market - Live News